Published in Gene Therapy Weekly, February 1st, 2001
This ribozyme targets several HBV RNA transcripts as well as HBV pregenomic RNA. HepBzyme represents a completely new approach to treating HBV, differing significantly from existing therapies. HepBzyme is RPI's fourth product candidate, the first three being Angiozyme, Heptazyme, and Herzyme. RPI intends to file an IND (Investigational New Drug) and complete a Phase I clinical trial for HepBzyme in 2001.
HepBzyme was selected based in part on antiviral activity screening in cell culture...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.